Clinical Trials Directory

Trials / Completed

CompletedNCT03297489

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Roswell Park Cancer Institute · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies how well intravital microscopy works in evaluating patients with primary peritoneal, fallopian tube, or stage IA-IV ovarian cancer. Intravital microscopic evaluation of tumor blood vessels, blood flow, immune cell interactions, and drug uptake may be eventually visualized and may lead to valuable prognostic information.

Detailed description

PRIMARY OBJECTIVES: I. To determine the feasibility of performing intravital microscopy on accessible human ovarian, primary peritoneal and fallopian tube cancers during their standard course of treatment (i.e., surgical debulking). SECONDARY OBJECTIVES: I. To determine the blood flow velocity of the tumor vessels and tissue penetration of fluorescein as a marker of tumor vessel permeability. OUTLINE: Patients receive fluorescein sodium injection intravenously (IV). Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery. After completion of study, patients are followed up for 30 days, at 1-3 weeks, and then up to 2 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREDiagnostic MicroscopyUndergo observation via intravital microscopy
DRUGFluorescein Sodium InjectionGiven IV
OTHERLaboratory Biomarker AnalysisCorrelative studies

Timeline

Start date
2017-11-06
Primary completion
2021-02-15
Completion
2021-02-15
First posted
2017-09-29
Last updated
2021-10-06

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03297489. Inclusion in this directory is not an endorsement.